Last Updated: September 23, 2026

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM Drug Patent Profile

Name: NAPROXEN AND ESOMEPRAZOLE MAGNESIUM Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

When do Naproxen And Esomeprazole Magnesium patents expire, and what generic alternatives are available?

Naproxen And Esomeprazole Magnesium is a drug marketed by Actavis Labs Fl Inc, Ajanta Pharma Ltd, Dr Reddys, Pharmobedient, and Sciegen Pharms. and is included in five NDAs.

The generic ingredient in NAPROXEN AND ESOMEPRAZOLE MAGNESIUM is esomeprazole magnesium; naproxen. There is one drug master file entry for this compound. Ten suppliers are listed for this compound. Additional details are available on the esomeprazole magnesium; naproxen profile page.

AI Deep Research

Questions you can ask:

What is the 5 year forecast for NAPROXEN AND ESOMEPRAZOLE MAGNESIUM?
What are the global sales for NAPROXEN AND ESOMEPRAZOLE MAGNESIUM?
What is Average Wholesale Price for NAPROXEN AND ESOMEPRAZOLE MAGNESIUM?

Summary for NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

US Patents:	0
Applicants:	5
NDAs:	5
Finished Product Suppliers / Packagers:	10
What excipients (inactive ingredients) are in NAPROXEN AND ESOMEPRAZOLE MAGNESIUM?	NAPROXEN AND ESOMEPRAZOLE MAGNESIUM excipients list
DailyMed Link:	NAPROXEN AND ESOMEPRAZOLE MAGNESIUM at DailyMed

Drug patent expirations by year for NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

Pharmacology for NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

Drug Class	Nonsteroidal Anti-inflammatory Drug Proton Pump Inhibitor
Mechanism of Action	Cyclooxygenase Inhibitors Cytochrome P450 2C19 Inhibitors Proton Pump Inhibitors

US Patents and Regulatory Information for NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actavis Labs Fl Inc	NAPROXEN AND ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium; naproxen	TABLET, DELAYED RELEASE;ORAL	204470-001	Aug 24, 2022		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Pharmobedient	NAPROXEN AND ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium; naproxen	TABLET, DELAYED RELEASE;ORAL	204920-001	Jul 20, 2021		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Ajanta Pharma Ltd	NAPROXEN AND ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium; naproxen	TABLET, DELAYED RELEASE;ORAL	213699-002	Oct 6, 2022	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Pharmobedient	NAPROXEN AND ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium; naproxen	TABLET, DELAYED RELEASE;ORAL	204920-002	Jul 20, 2021		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Actavis Labs Fl Inc	NAPROXEN AND ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium; naproxen	TABLET, DELAYED RELEASE;ORAL	204470-002	Aug 24, 2022		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.